What is the appropriate cephalexin (Keflex) regimen for an uncomplicated urinary tract infection in a healthy adult, including dosing, adjustments for renal impairment, pregnancy, allergies, and alternative options?

Cephalexin (Keflex) for Urinary Tract Infections

Standard Dosing for Uncomplicated UTI

For uncomplicated cystitis in adults, cephalexin 500 mg orally twice daily for 7 days is as effective as the traditional four-times-daily regimen and should be the preferred dosing strategy to improve adherence. 1, 2, 3

• The FDA-approved dosing for uncomplicated cystitis is 500 mg every 12 hours for 7–14 days in patients over 15 years of age. 4
• Multiple recent studies demonstrate that twice-daily dosing achieves clinical success rates of 81–87%, with no statistically significant difference compared to four-times-daily administration (treatment failure 12.7% vs 17%, P = 0.343). 1, 2, 3
• Cephalexin achieves urinary concentrations of 500–1000 mcg/mL following 250–500 mg oral doses, far exceeding the minimum inhibitory concentration for common uropathogens. 5

When Cephalexin Is Appropriate

Cephalexin should be reserved for uncomplicated UTIs caused by non-ESBL-producing E. coli, Klebsiella pneumoniae, or Proteus mirabilis that are susceptible to cefazolin, and only when first-line agents (nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin) cannot be used due to allergy or resistance. 6, 3

• The 2011 IDSA guidelines recommend β-lactam antibiotics as alternative rather than first-line agents for uncomplicated UTI. 1
• Cephalexin is FDA-approved for genitourinary infections caused by Klebsiella pneumoniae when the isolate is susceptible to cefazolin; therapy must be guided by urine culture and susceptibility testing. 4
• First- and second-generation cephalosporins are generally ineffective against Enterobacter species, and resistance is increasingly common among Enterobacteriaceae, especially ESBL-producing strains. 7

Critical Limitations and Contraindications

Do not use cephalexin for complicated UTIs, pyelonephritis, ESBL-producing organisms, or when upper-tract involvement is suspected, as it has insufficient tissue penetration and markedly higher failure rates (15–30%) compared to fluoroquinolones or trimethoprim-sulfamethoxazole. 7, 6

• ESBL-producing Klebsiella pneumoniae is resistant to cephalexin; treatment requires carbapenems, newer β-lactam/β-lactamase inhibitor combinations, or fluoroquinolones based on susceptibility. 7
• Oral cephalexin is inadequate for upper-tract infections such as pyelonephritis without prior parenteral therapy because tissue penetration is insufficient. 7
• Cephalexin should not be used for complicated UTIs that require broader antimicrobial coverage (e.g., sepsis, immunocompromised hosts, healthcare-associated infections); preferred agents include ceftriaxone, fluoroquinolones, or carbapenems. 7

Renal Dose Adjustment

Patients with creatinine clearance less than 30 mL/min require a 50% reduction in cephalexin dosage, proportional to the degree of renal impairment. 5

• Standard dosing (500 mg twice daily) should be reduced to 250 mg twice daily or 500 mg once daily when CrCl < 30 mL/min. 5
• No dose adjustment is needed for patients with eGFR ≥ 30 mL/min. 5

Pregnancy and Allergy Considerations

Cephalexin is safe in pregnancy and can be used in patients with sulfonamide allergy, as there is no cross-reactivity between β-lactam antibiotics and sulfonamide antimicrobials. 7

• Sulfonamide antimicrobials possess an aromatic amine at the N4 position that is absent from β-lactams, explaining the lack of cross-reactivity. 7
• Patients with documented penicillin allergy should not receive cephalexin due to potential cross-reactivity between penicillins and cephalosporins (approximately 1–10% risk). 7

Alternative Options When Cephalexin Is Unsuitable

When cephalexin cannot be used, select alternatives based on susceptibility and clinical context:

• For uncomplicated cystitis: Nitrofurantoin 100 mg twice daily for 5 days, trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days, or fosfomycin 3 g single dose are preferred first-line agents. 7, 6
• For complicated UTI or pyelonephritis: Initiate ceftriaxone 1–2 g IV/IM once daily, then transition to oral fluoroquinolones (levofloxacin 750 mg daily for 5–7 days or ciprofloxacin 500–750 mg twice daily for 7 days) when susceptible and local resistance < 10%. 7
• For ESBL-producing organisms: Use carbapenems (ertapenem 1 g once daily, meropenem 1 g three times daily) or newer β-lactam/β-lactamase inhibitor combinations (ceftazidime/avibactam, meropenem/vaborbactam). 7

Common Pitfalls to Avoid

• Do not assume all Klebsiella isolates are susceptible to cephalexin; resistance patterns vary widely by geographic region and healthcare setting, making culture-guided therapy essential. 7
• Do not apply short-course (3–5 day) regimens recommended for uncomplicated cystitis when using cephalexin; the FDA-approved duration is 7–14 days. 4
• Do not use cephalexin for catheter-associated UTI, male patients (where prostatitis cannot be excluded), or any patient with underlying urological abnormalities, as these are complicated infections requiring broader coverage and longer duration (7–14 days). 7
• Do not prescribe cephalexin four times daily when twice-daily dosing is equally effective and improves adherence. 1, 2, 3